Antiestrogens and SERMs (selective estrogen receptor modulators) such as tamoxifen and raloxifene are the most widely used agents in the treatment of hormone-responsive breast cancer and have proved to be very effective in breast cancer prevention. They are likely to play increasingly important roles in menopausal hormone replacement therapy as well. While it has long been known that the estrogen receptor (ER) is required for the actions of estrogens and SERMs, it is increasingly appreciated that the activity of the ER and the tissue selectivity of SERMs are markedly influenced by coregulator proteins. Also, the action of ER influences the expression pattern of a remarkable number of genes through a diversity of modes. In this project, we will combine modern technologies in an innovative two-pronged approach to understanding the molecular basis of SERM action: (a) a targeted investigation of the role of an ER-specific coregulator, REA (repressor of estrogen receptor activity), through the development of an REA knockout mouse, together with comparative studies on the influence of other corepressors in the action of SERMs, and (b) a global analysis of gene regulation by SERMs using microarrays, together with complementary bioinformatic, molecular, and biochemical analyses of regulated function. This research should provide a clearer understanding of the gene networks through which SERMs act, the cellular factors that determine SERM effectiveness and tissue selectivity, and the gene-regulating activities that contribute to their beneficial anti-proliferative and tumor suppressive actions in breast cancer treatment and prevention, and provide the optimal balance of tissue selective activities for hormone replacement therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA018119-32
Application #
7385132
Study Section
Endocrinology Study Section (END)
Program Officer
Sathyamoorthy, Neeraja
Project Start
1978-12-01
Project End
2010-04-30
Budget Start
2008-05-01
Budget End
2010-04-30
Support Year
32
Fiscal Year
2008
Total Cost
$322,811
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Physiology
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Aghmesheh, Morteza; Saxena, Akshat; Niknam, Farshid (2015) BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas. Asia Pac J Clin Oncol 11:135-41
Minutolo, Filippo; Macchia, Marco; Katzenellenbogen, Benita S et al. (2011) Estrogen receptor ? ligands: recent advances and biomedical applications. Med Res Rev 31:364-442
Madak-Erdogan, Zeynep; Lupien, Mathieu; Stossi, Fabio et al. (2011) Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol Cell Biol 31:226-36
Chambliss, Ken L; Wu, Qian; Oltmann, Sarah et al. (2010) Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120:2319-30
Charn, Tze Howe; Liu, Edison Tak-Bun; Chang, Edmund C et al. (2010) Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol 24:47-59
Santollo, Jessica; Katzenellenbogen, Benita S; Katzenellenbogen, John A et al. (2010) Activation of ER? is necessary for estradiol's anorexigenic effect in female rats. Horm Behav 58:872-7
Stender, Joshua D; Kim, Kyuri; Charn, Tze Howe et al. (2010) Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 30:3943-55
Kieser, Karen J; Kim, Dong Wook; Carlson, Kathryn E et al. (2010) Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J Med Chem 53:3320-9
Waibel, Michael; Kieser, Karen J; Carlson, Kathryn E et al. (2009) Phenethyl pyridines with non-polar internal substituents as selective ligands for estrogen receptor beta. Eur J Med Chem 44:3560-70
Hartmaier, R J; Walenkamp, M J E; Richter, A S et al. (2009) A case of premature thelarche with no central cause or genetic variants within the estrogen receptor signaling pathway. J Pediatr Endocrinol Metab 22:751-8

Showing the most recent 10 out of 154 publications